Citations

Showing 10 of 108119 citations.

Carotid Artery Plaque Calcifications: Lessons From Histopathology to Diagnostic Imaging
Saba, Luca , Nardi, Valentina , Cau, Riccardo , Gupta, Ajay, Kamel, Hooman , Suri, Jasjit S., Balestrieri, Antonella , Congiu, Terenzio, Butler, Anthony P.H., Gieseg, Steven, Sanfilippo, Roberto, Puig, Josep, Yang, Qi, Mannelli, Lorenzo, Faa, Gavino, Yang, Qi , Fanni, Daniela , Cerrone, Giulia , Lanzino, Giuseppe , Cau, Riccardo , Balestrieri, Antonella , Kamel, Hooman , Nardi, Valentina , Saba, Luca , Gupta, Ajay, Suri, Jasjit S., Congiu, Terenzio, Butler, Anthony P.H., Gieseg, Steven, Sanfilippo, Roberto, Puig, Josep, Yang, Qi, Mannelli, Lorenzo, Faa, Gavino

Mayo Clinic

Stroke | November 10, 2021 | Volume: 53 | Issue: 1 | Pages: 290-297

10.1161/strokeaha.121.035692 | PMID 34753301 Get It

The role of calcium in atherosclerosis is controversial and the relationship between vascular calcification and plaque vulnerability is not fully understood. Although calcifications are present in ≈50% to 60% of carotid plaques, their association with cerebrovascular ischemic events remains unclear. In this review, we summarize current understanding of carotid plaque calcification. We outline the role of calcium in atherosclerotic carotid disease by analyzing laboratory studies and histopathologic studies, as well as imaging findings to understand clinical implications of carotid artery calcifications. Differences in mechanism of calcium deposition express themselves into a wide range of calcification phenotypes in carotid plaques. Some patterns, such as rim calcification, are suggestive of plaques with inflammatory activity with leakage of the vasa vasourm and intraplaque hemorrhage. Other patterns such as dense, nodular calcifications may confer greater mechanical stability to the plaque and reduce the risk of embolization for a given degree of plaque size and luminal stenosis. Various distributions and patterns of carotid plaque calcification, often influenced by the underlying systemic pathological condition, have a different role in affecting plaque stability. Modern imaging techniques afford multiple approaches to assess geometry, pattern of distribution, size, and composition of carotid artery calcifications. Future investigations with these novel technologies will further improve our understanding of carotid artery calcification and will play an important role in understanding and minimizing stroke risk in patients with carotid plaques.
Race as Risk Factor: Always Ask “Why?”
Melson, Valerie A. , Lewis, Derrick B. , Maciejko, Laura A. , Melson, Valerie

Mayo Clinic

Academic Medicine | November 10, 2021 | Volume: 97 | Issue: 6 | Pages: 775-776

10.1097/acm.0000000000004504 | PMID 34753857 Get It

How I treat cardiovascular complications in patients with lymphoid malignancies
Herrmann, Joerg , McCullough, Kristen , McCullough, Kristen B , Habermann, Thomas M.

Mayo Clinic

Blood | November 9, 2021 | Volume: 139 | Issue: 10 | Pages: 1501-1516

10.1182/blood.2019003893 | PMID 34752600 Get It

Abstract The prognosis of several lymphoid malignancies has improved through development of novel therapies, combination with traditional chemotherapies, and delineation of appropriate therapeutic sequencing. Toxicities that are arising because of prolonged or multiple sequential therapeutic interventions are becoming increasingly impactful. Among the broad spectrum of complications that patients with lymphoid malignancies may experience, cardiovascular toxicities are significant in terms of morbidity and mortality. The entire cardiovascular system can be affected, but cardiomyopathy, heart failure, and arrhythmias remain of greatest concerns with the use of anthracyclines, hematopoietic stem cell transplantation, and radiation therapy in patients with lymphoid malignancies. These aspects will be covered in this article within the framework of case-based discussions. Key to the management of cardiovascular complications in patients with lymphoid malignancies is awareness and preparedness across the cancer continuum. Baseline risk stratification helps to direct surveillance and early intervention efforts before, during, and after cancer therapy, which are paramount for the best possible outcomes. Along these lines, the overall goal is to enable the best possible therapies for lymphoid malignancies without the complications of clinically significant cardiovascular events.
Mortality from snakebite envenomation: an analysis from the Global Burden of Disease Study 2019
Roberts, Nicholas L S , Johnson, Emily K. , Zeng, Scott , Hamilton, Erin B, Alahdab, Fares , Alipour, Vahid, Andrei, Cătălina Liliana , Arabloo, Jalal , Badiye, Ashish , Bakkannavar, Shankar M , Bhalla, Ashish, Bijani, Ali , Cai, Tianji , Carvalho, Félix , Chu, Dinh‐Toi , Couto, Rosa A S, Desta, Abebaw Alemayehu, Earl, Lucas, Eftekhari, Aziz , Esmaeilzadeh, Firooz , Gebregiorgis, Birhan Gebresillassie , Ghashghaee, Ahmad , Golechha, Mahaveer , Haque, Syed Arefinul , Kapoor, Neeti , Khan, Ejaz Ahmad , Khundkar, Roba , Krishan, Kewal , Kumar, G Anil , Lim, Stephen S , Manafi, Navid , Miller, Ted R. , Mokdad, Ali A, Monteiro, Francis N.P., Moradi, Maryam , Nguyen, Cuong Tat , Nguyen, Huong Lan Thi , Ostroff, Samuel M, Pham, Hai Quang , Rabiee, Navid , Rao, Sowmya R. , Rawaf, David Laith , Reiner, Robert C. , Samy, Abdallah M , Sawhney, Monika, Schwebel, David C. , Senthilkumaran, Subramanian , Shaikh, Masood Ali , Tovani‐Palone, Marcos Roberto , Travillian, Ravensara S., Velazquez, Diana Zuleika , Zhang, Zhi‐Jiang , Naghavi, Mohsen , Dandona, Rakhi , Dandona, Lalit , James, Spencer L , Murray, Christopher, Hay, Simon I , Vos, Theo , Abdoli, Amir , Ancuceanu, Robert , Anvari, Davood , Ausloos, Marcel , Awedew, Atalel Fentahun , Bhardwaj, Nikha , Bhardwaj, Pankaj , Bhaumik, Soumyadeep , Boloor, Archith , Dai, Xiaochen , Do, Hoa , Farzadfar, Farshad , Fernandes, Eduarda , Filip, Irina , Foroutan, Masoud , Franklin, Richard C. , Gaidhane, Abhay Motiramji , Gebremichael, Berhe , Hamidi, Samer , Haque, Syed, Hayat, Khezar , Herţeliu, Claudiu , Ilesanmi, Olayinka Stephen , Islam, M. Mofizul , Jagnoor, Jagnoor , Kanchan, Tanuj , Khatib, Mahalaqua Nazli , Kumar, Nithin , Landires, Iván , Madadin, Mohammed , Maled, Venkatesh , Marczak, Laurie B. , Menezes, Ritesh G. , Meretoja, Tuomo J , Mohammadian-Hafshejani, Abdollah , Nayak, Vinod C , Núñez-Samudio, Virginia , Padubidri, Jagadish Rao , Pinheiro, Marina , Pirestani, Majid , Zahiruddin, Quazi Syed , Radfar, Amir , Rahimi‐Movaghar, Vafa , Rastogi, Prateek , Rawaf, Salman , Sahebkar, Amirhossein , Skryabin, Valentin Yurievich , Skryabina, Anna Aleksandrovna , Soheili, Amin , Stokes, Mark Andrew , Thapar, Rekha , Tran, Bach Xuan , Pigott, David M. , Ong, Sok King , Alahdab, Fares

Mayo Clinic

No container title available | November 9, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1021472/v1 Get It

Abstract Venomous snakebite is an important cause of preventable death. The World Health Organization (WHO) set a goal to halve snakebite mortality by 2030. We used verbal autopsy and vital registration data to model the proportion of venomous animal deaths due to snakes by location, age, year, and sex, and applied these proportions to venomous animal contact mortality estimates from the Global Burden of Disease 2019 study. In 2019, 63,400 people (95% uncertainty interval 38,900–78,600) died globally from snakebites, which was equal to an age-standardized mortality rate (ASMR) of 0.8 deaths (0.5–1.0) per 100,000 and represents a 36% (2–49) decrease in ASMR since 1990. India had the greatest number of deaths in 2019, equal to an ASMR of 4.0 per 100,000 (2.3-5.0). We forecast mortality will continue to decline, but not sufficiently to meet the WHO’s goals. Improved data collection should be prioritized to help target interventions, improve burden estimation, and monitor progress.
Uncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesity
Reddy, Yogesh N.V. , Sorimachi, Hidemi, Borlaug, Barry A. , Obokata, Masaru , Melenovský, Vojtěch , Borlaug, Barry A , Nishimura, Rick , Jarolı́m, Petr

Mayo Clinic

European Journal of Heart Failure | November 9, 2021 | Volume: 24 | Issue: 2 | Pages: 353-361

10.1002/ejhf.2377 | PMID 34755429 Get It

Abstract Aims Patients with obesity frequently present with dyspnoea. Biomarkers that reflect wall stress are often used to evaluate circulatory congestion and help determine whether dyspnoea is of cardiac causes. Patients with obesity display greater external restraint on the heart, which may alter relationships between intravascular pressures and stress markers. Methods and results Subjects with unexplained dyspnoea ( n = 212) underwent cardiac catheterization with simultaneous echocardiography. Blood sampling was performed in a subset ( n = 58). Relationships between echocardiographic and blood biomarkers of circulatory congestion and directly‐measured haemodynamics were compared between participants with severe obesity [body mass index (BMI) ≥35 kg/m 2 , Group B) and those without (BMI <35 kg/m 2 , Group A). Circulatory congestion was assessed by pulmonary capillary wedge pressure (PCWP), and vascular distending pressure was assessed by left ventricular transmural pressure (LVTMP). As compared to Group A, participants in Group B displayed higher PCWP relative to N‐terminal pro‐B‐type natriuretic peptide, mid‐regional pro‐atrial natriuretic peptide, troponin T, and growth differentiation factor‐15 (all p < 0.01). In contrast, the relationships between LVTMP and the biomarkers were superimposable. Echocardiographic biomarkers revealed the same pattern: PCWP was higher for any E/e′ ratio in Group B compared to Group A, but the relationship between LVTMP and E/e′ was similar. In contrast, levels of C‐terminal pro‐endothelin‐1 and mid‐regional pro‐adrenomedullin were more robustly correlated with PCWP (r = 0.67 and r = 0.62, both p < 0.0001), with no differential relationship based upon BMI. Conclusions Non‐invasive haemodynamic markers underestimate circulatory congestion in patients with obesity, an effect that appears related to uncoupling between cardiac wall stress and intravascular pressures. This may lead to systematic under‐recognition of congestion in patients with obesity.
Feasibility of Using Real-world Data to Emulate Postapproval Confirmatory Clinical Trials of Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval
Wallach, Joshua D. , Zhang, Audrey D. , Skydel, Joshua J. , Bartlett, Victoria , Dhruva, Sanket S. , Shah, Nilay D. , Wallach, Joshua D , Ross, Joseph S.

Mayo Clinic

JAMA Network Open | November 9, 2021 | Volume: 4 | Issue: 11 | Pages: e2133667

10.1001/jamanetworkopen.2021.33667 | PMID 34751763 Get It

Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin
Fontana, Elisa , Meyers, Jeff, Sobrero, Alberto F. , Iveson, Timothy , Shields, Anthony F., Taı̈eb, Julien , Yoshino, Takayuki , Souglakos, Ioannis, Smyth, Elizabeth C., Lordick, Florian, Moehler, Markus , Giraut, Anne, Harkin, Andrea , Labianca, Roberto, Meyerhardt, Jeffrey, Boukovinas, Ioannis , Saunders, Mark, Vernerey, Dewi, Georgoulias, Vassilis, Ben‐Aharon, Irit , Shi, Qian , Meyerhardt, Jeffrey A. , Sobrero, Alberto , André, Thierry , Boukovinas, Ioannis , Lonardi, Sara , Oki, Eiji , Ben-Aharon, Irit , Shi, Qian , Meyerhardt, Jeffrey A , Iveson, Timothy J , Yoshino, Takayuki , Taieb, Julien , Fontana, Elisa , Meyers, Jeff, Shields, Anthony F., Souglakos, Ioannis, Smyth, Elizabeth C., Lordick, Florian, Moehler, Markus , Giraut, Anne, Harkin, Andrea , Labianca, Roberto, Saunders, Mark, Vernerey, Dewi, Georgoulias, Vassilis

Mayo Clinic

Journal of Clinical Oncology | November 9, 2021 | Volume: 39 | Issue: 36 | Pages: 4009-4019

10.1200/jco.21.02008 | PMID 34752136 Get It

PURPOSE Early-onset (EO) colorectal cancer (CRC, age < 50 years) incidence is increasing. Decisions on optimal adjuvant therapy should consider treatment adherence, adverse events, and expected outcomes in a population with life expectancy longer than later-onset (LO) CRC (age ≥ 50 years). MATERIALS AND METHODS Individual patient data from six trials in the International Duration Evaluation of Adjuvant Chemotherapy database were analyzed. Characteristics, treatment adherence, and adverse events in stage II or III EO-CRC and LO-CRC were compared. To reduce confounders of non–cancer-related deaths because of age or comorbidities, time to recurrence (3-year relapse-free rate) and cancer-specific survival (5-year cancer-specific mortality rate) were considered. RESULTS Out of 16,349 patients, 1,564 (9.6%) had EO-CRC. Compared with LO-CRC, EO-CRC had better performance status (86% v 80%, P < .01), similar T stage (% T1-3/T4: 76/24 v 77/23, P = .97), higher N2 disease rate (24% v 22%, P < .01), more likely to complete the planned treatment duration (83.2% v 78.2%, P < .01), and received a higher treatment dose intensity, especially with 6-month regimens. Gastrointestinal toxicity was more common in EO-CRC; hematologic toxicity was more frequent in LO-CRC. Compared with LO-CRC, significantly worse cancer-specific outcomes were demonstrated especially in high-risk stage III EO-CRC: lower 3-year relapse-free rate (54% v 65%; hazard ratio [HR] 1.33; 95% CI, 1.14 to 1.55; P value < .001) and higher 5-year cancer-specific mortality rate (24% v 20%; HR 1.21; 95% CI, 1.00 to 1.47; P value < .06). In this subgroup, no difference was observed with 3 or 6 months of therapy, with equally poor disease-free survival rates (57% v 56%; HR 0.97; 95% CI, 0.73 to 1.29; P value = .85). CONCLUSION Young age is negatively prognostic in high-risk stage III CRC and associated with significantly higher relapse rate; this is despite better treatment adherence and higher administered treatment intensity, suggesting more aggressive disease biology.
Hip decompression combined with bone marrow concentrate and platelet-rich plasma for corticosteroid-induced osteonecrosis of the femoral head
Houdek, Matthew T. , Smith, John-Rudolph H. , Smith, John R. , Wyles, Cody C. , Houdek, Matthew T , Smith, John-Rudolph , Terzic, André , Behfar, Atta , Sierra, Rafael J.

Mayo Clinic

Bone & Joint Open | November 9, 2021 | Volume: 2 | Issue: 11 | Pages: 926-931

10.1302/2633-1462.211.bjo-2021-0132.r1 | PMID 34751583 Get It

Aims Bone marrow-derived mesenchymal stem cells obtained from bone marrow aspirate concentrate (BMAC) with platelet-rich plasma (PRP), has been used as an adjuvant to hip decompression. Early results have shown promise for hip preservation in patients with osteonecrosis (ON) of the femoral head. The purpose of the current study is to examine the mid-term outcome of this treatment in patients with precollapse corticosteroid-induced ON of the femoral head. Methods In all, 22 patients (35 hips; 11 males and 11 females) with precollapse corticosteroid-induced ON of the femoral head underwent hip decompression combined with BMAC and PRP. Mean age and BMI were 43 years (SD 12) and 31 kg/m² (SD 6), respectively, at the time of surgery. Survivorship free from femoral head collapse and total hip arthroplasty (THA) and risk factors for progression were evaluated at minimum five-years of clinical follow-up with a mean follow-up of seven years (5 to 8). Results Survivorship free from femoral head collapse and THA for any reason was 84% and 67% at seven years postoperatively, respectively. Risk factors for conversion to THA included a high preoperative modified Kerboul angle (grade 3 or 4) based on preoperative MRI (hazard ratio (HR) 3.96; p = 0.047) and corticosteroid use at the time of decompression (HR 4.15; p = 0.039). The seven-year survivorship for patients with grade 1 or 2 Kerboul angles for conversion to THA for articular collapse, and THA for any reason, were 96% and 72%, respectively, versus THA for articular collapse and THA for any reason in patients with grade 3 or 4 Kerboul angles of 40% (p = 0.003) and 40% (p = 0.032). Conclusion At seven years, hip decompression augmented with BMAC and PRP provided a 67% survivorship free from THA in patients with corticosteroid-induced ON. Ideal candidates for this procedure are patients with low preoperative Kerboul angles and can stop corticosteroid treatment prior to decompression. Cite this article: Bone Jt Open 2021;2(11):926–931.
Varus-valgus constrained insert with posterior-stabilized femoral components in complex primary total knee arthroplasties
Limberg, Afton K. , Hanssen, Arlen D. , Pagnano, Mark W. , Wyles, Cody C. , Taunton, Michael J. , Abdel, Matthew P.

Mayo Clinic

Bone & Joint Open | November 9, 2021 | Volume: 2 | Issue: 11 | Pages: 921-925

10.1302/2633-1462.211.bjo-2021-0134.r1 | PMID 34751585 Get It

Aims Varus-valgus constrained (VVC) devices are typically used in revision settings, often with stems to mitigate the risk of aseptic loosening. However, in at least one system, the VVC insert is compatible with the primary posterior-stabilized (PS) femoral component, which may be an option in complex primary situations. We sought to determine the implant survivorship, radiological and clinical outcomes, and complications when this VVC insert was coupled with a PS femur without stems in complex primary total knee arthroplasties (TKAs). Methods Through our institution’s total joint registry, we identified 113 primary TKAs (103 patients) performed between 2007 and 2017 in which a VVC insert was coupled with a standard cemented PS femur without stems. Mean age was 68 years (SD 10), mean BMI was 32 kg/m2 (SD 7), and 59 patients (50%) were male. Mean follow-up was four years (2 to 10). Results The five-year survivorship free from aseptic loosening was 100%. The five-year survivorship free from any revision was 99%, with the only revision performed for infection. The five-year survivorship free from reoperation was 93%. The most common reoperation was treatment for infection (n = 4; 4%), followed by manipulation under anaesthesia (MUA; n = 2; 2%). Survivorship free from any complication at five years was 90%, with superficial wound infection as the most frequent (n = 4; 4%). At most recent follow-up, two TKAs had non-progressive radiolucent lines about both the tibial and femoral components. Knee Society Scores improved from 53 preoperatively to 88 at latest follow-up (p < 0.001). Conclusion For complex primary TKA in occasional situations, coupling a VVC insert with a standard PS femur without stems proved reliable and durable at five years. Longer-term follow-up is required before recommending this technique more broadly. Cite this article: Bone Jt Open 2021;2(11):921–925.
Bile Acid Diarrhea in Adults and Adolescents
Camilleri, Michael , Nurko, Samuel , Nurko, Samuel

Mayo Clinic

Neurogastroenterology & Motility | November 9, 2021 | Volume: 34 | Issue: 4 | Pages: No page available

10.1111/nmo.14287 | PMID 34751982 Get It

ABSTRACTBackgroundBile acids are central to enterohepatic signaling pathways activated through natural receptors, farnesoid X receptor [FXR mediates synthesis of fibroblast growth factor‐19 (FGF‐19)], and G protein‐coupled bile acid receptor 1 (GPBAR1, also known as TGR5). Although bile acid diarrhea (BAD) is more commonly encountered in ileal resection or disease, there is evidence documenting “idiopathic” BAD in about 20% of adolescents and 30% of adults presenting with chronic, non‐bloody diarrhea often attributed to irritable bowel syndrome. Mechanism(s) leading to increased hepatic synthesis and colonic bile acid levels in “idiopathic” BAD include reduced synthesis of FGF‐19 by the ileal mucosa, or genetic variation in hepatocyte proteins klotho β and FGF receptor 4 (FGFR4) that mediate negative feedback of bile acid synthesis. Purpose: The objective of this review is to summarize the diagnosis of BAD in adults and adolescents. In addition to 75SeHCAT retention for diagnosis of BAD, studies have validated fasting serum 7αC4 and FGF‐19, respectively, by‐product and inhibitor of hepatic bile acid synthesis, as well as fecal bile acid measurements. These assays are widely available through reference laboratories, and they are being simplified (eg, measurement of primary fecal bile acids in a random stool sample). BAD has also been identified as a co‐factor contributing to persistent diarrhea in other diseases in remission including inflammatory bowel disease, microscopic colitis, celiac disease, and neuroendocrine tumors. In summary, advances in diagnosis of BAD provide opportunities for generalists and pediatric and adult gastroenterologists to provide targeted treatment for BAD presenting as chronic non‐bloody diarrhea.